Category: Pharmaceutical Industry
-
AstraZeneca defends record patent invalidation claims in China
The UK pharma giant has defeated 33 invalidation claims brought by Chinese generics manufacturers against crystal form patents related to its highest-selling diabetes drug.
-
Pfizer brought UPC revocation action 9 seconds after midnight on grant date, argues Glaxo jumped the gun with infringement filing
Pharmaceutical giants GlaxoSmithKline and Pfizer are embroiled in an interesting UPC venue fight that involves questions of timing.
-
China’s Supreme People’s Court settles mRNA patent, trade secrets litigation under President Xi’s new ‘Fengqiao’ dispute model
Chinese courts are imposing mediation on more and more cases under the new order, including those involving patent infringement.
-
Northwestern University amended license agreement with inventors’ startup, now suing Moderna in Delaware over LNP patents
Northwestern University is suing Moderna over lipid nanoparticle (LNP) patents.
-
UPC’s Dusseldorf LD denies PI in Novartis v. Celltrion: some preparations for product launch aren’t sufficient for imminent infringement
The UPC’s Dusseldorf LD unsurprisingly denied a preliminary injunction motion by Novartis over Celltrion’s preparations for the launch of a biosimilar.
-
UPC’s Paris CD keeps Edwards Lifesciences patent on prosthetic heart valve alive based on late-filed auxiliary request
The UPC’s Paris Central Division has upheld an Edwards Lifesciences patent in an amended form on a procedural basis that will result in an important clarification by the Court of Appeal.
-
UPC’s Dusseldorf Local Division grants 10x Genomics preliminary injunction against Curio, clarifies legal standard in four contexts
Today the Dusseldorf Local Division of the Unified Patent Court issued a preliminary injunction in 10x Genomics’ favor against Curio Bioscience.
-
GlaxoSmithKline sues Pfizer, BioNTech in District of Delaware over mRNA patents allegedly infringed by COVID vaccine
GlaxoSmithKline, one of the world’s largest pharmaceutical companies, is suing Pfizer and BioNTech in the District of Delaware, alleging that their COVID-19 vaccines infringe GSK’s mRNA patents.